NMN vs. NR vs. Nicotinamide: Which Raises NAD+?

NMN can cost about 10 times as much as plain nicotinamide. If you are paying that premium to raise NAD+, a new human trial gives NMN and NR the edge—but not an edge over each other. At 1 g per day for 14 days, both roughly doubled whole-blood NAD+ in healthy young adults. Nicotinamide did not produce a sustained increase at the lower dose tested.

That answers the narrow biomarker question. It does not answer the health question. Higher blood NAD+ has yet to produce consistent improvements in metabolic health, muscle function, or liver function across randomized trials. A bigger number on a lab report is still a surrogate outcome, not proof of better aging.

NR and NMN tied on whole-blood NAD+

In a 2026 open-label, four-arm randomized controlled trial, Christen et al. assigned 65 young, lean, healthy adults in the modified intention-to-treat analysis to NR 1 g/day (n=16), NMN 1 g/day (n=15), nicotinamide 0.5 g/day (n=17), or placebo (n=17) for 14 days. Participants had a mean age of 34.7 years and body-mass indices between 21 and 24 kg/m².

The primary endpoint was whole-blood NAD+. Compared with placebo, NR increased NAD+ by a mean 49.4 µM (95% CI, 39.5 to 59.3; P<0.001). NMN increased it by 43.1 µM (95% CI, 32.7 to 53.4; P<0.001). The two effects did not differ significantly from each other. Nicotinamide produced no significant chronic increase in whole-blood NAD+ (P=0.461).

If your sole goal is a measurable rise in whole-blood NAD+, the trial supports NR and NMN at 1 g/day. It does not support paying more for NMN than NR. It also does not establish that a typical 300 mg retail dose will do the same thing: the trial tested about 3.3 times that amount for NR and NMN.

Nicotinamide lost this round, but the comparison has a catch

Nicotinamide, also called niacinamide, received 0.5 g/day while NR and NMN received 1 g/day. The researchers partly adjusted the comparison on a molar basis—nicotinamide was 4.1 mmol/day, NR 3.4 mmol/day, and NMN 3.0 mmol/day—but the gram doses still differed. No dose-escalation arm tested whether 1 g/day or more of nicotinamide could sustain higher whole-blood NAD+.

The trial's acute sampling offers one possible explanation for the nicotinamide result. Whole-blood nicotinamide peaked at about one hour after dosing, then its methylated excretion products, MeNam and MeXPY, rose. That pattern fits rapid catabolism after oral intake rather than the cumulative NAD+ buildup observed with NR and NMN. It does not prove that nicotinamide can never raise NAD+ chronically, only that it failed under this specific dose and 14-day protocol.

The NR-versus-NMN marketing story may be less interesting than it looks

Christen and colleagues used metabolomics in blood, urine, and feces, plus four-hour pharmacokinetic sampling on day 1 and day 14. NR and NMN, but not nicotinamide, increased urinary nicotinic acid riboside and nicotinuric acid. A post-hoc analysis also detected higher whole-blood NAAD, an intermediate in the nicotinic-acid, or Preiss-Handler, pathway.

The authors' metabolite pattern raises a plausible hypothesis: gut microbes may deamidate NR and NMN to nicotinic acid before the body rebuilds NAD+. If that is correct, the two products may converge on the same metabolic route after you swallow them. A 2023 twin study of NR also reported changes in gut microbiota alongside increases in NAD+ across whole blood, PBMCs, urine, skeletal muscle, and brain tissue at doses ranging from 300 to 2,000 mg/day. Read the Lapatto et al. twin trial as support for an NR–gut interaction, not proof that gut microbes explain the head-to-head result.

The mechanism remains unproven in humans. The Christen trial did not include microbiome sequencing, an antibiotic comparison, or an ex vivo conversion assay. More than 85% of NAAD measurements were below the lower limit of quantification, 0.02 µM, which weakens confidence in that post-hoc signal. Interesting metabolite clues are not the same as a causal map of the human gut.

Blood NAD+ is not a health outcome

The most encouraging functional NMN study remains specific to a specific population. In a double-blind placebo-controlled trial, Yoshino et al. gave 250 mg/day of NMN for 10 weeks to prediabetic postmenopausal women, with 25 participants per group. NMN increased skeletal-muscle NAD+ and improved insulin-stimulated glucose disposal. That is a tissue-level functional outcome, and it matters. But it cannot establish that healthy younger adults—or the broader market for NAD+ supplements—will get the same benefit.

NR has also produced promising biological findings in narrower settings. The 2023 twin study reported improved muscle mitochondrial biogenesis and satellite-cell differentiation with NR. A separate double-blind crossover placebo-controlled trial found that NR increased NAD+ in people with Werner syndrome, a rare progeroid disorder. The Werner syndrome trial expands evidence that NR can raise NAD+ beyond healthy volunteers, but it does not turn a rare genetic-disease result into a longevity claim for healthy people.

When researchers pool randomized NMN trials that measure outcomes people actually care about, the picture gets much less tidy. A 2025 systematic review and meta-analysis by Zhang et al. found inconsistent, often null effects on glucose and lipid metabolism in adults. A 2026 meta-analysis by Wang et al. found heterogeneous and often non-significant effects on muscle and liver function in middle-aged and older adults.

NR and NMN can raise a blood biomarker. The evidence does not yet show that this reliably improves metabolic health, muscle performance, or liver function in the aging adults most likely to buy them.

Why the trial cannot settle the longevity question

The head-to-head design is useful, but its scope is narrow. It lasted only 14 days, enrolled 15 to 17 people per active arm, and measured whole-blood NAD+ as its primary endpoint. It cannot determine whether NAD+ stays elevated for months, whether different tissues respond similarly, or whether responders differ by baseline NAD+, sex, age, or microbiome.

The population creates a second problem. Young, lean, healthy adults may not have the tissue-level NAD+ deficits that motivate supplementation in later life. Skeletal muscle, liver, and brain matter more to aging claims than blood alone, yet the head-to-head trial did not sample those tissues. Studies of other candidate precursors, such as trigonelline research in aging and sarcopenia, reinforce that tissue-specific biology deserves direct measurement rather than inference from blood.

Open-label allocation also leaves subjective secondary outcomes vulnerable to expectation effects, although the main NAD+ endpoint is a laboratory measurement. Finally, publication bias remains possible: published positive biomarker trials may make NAD+ elevation look more uniform than it is. The functional meta-analyses help address a broader body of trials, but they answer a different question.

What to buy, if you still want an NAD+ precursor

For a short-term rise in whole-blood NAD+, NR and NMN tied at 1 g/day in the only direct comparison described here. The evidence gives no practical reason to choose NMN over NR for that endpoint. Nicotinamide at 0.5 g/day did not sustain higher whole-blood NAD+, but the unequal gram doses prevent a clean claim that it is categorically inferior.

For better health, strength, liver function, or longer life, the evidence does not justify a premium purchase. NMN has one notable insulin-sensitivity result in prediabetic postmenopausal women, and NR has encouraging tissue and mechanistic findings. Those results warrant more trials with older participants, longer follow-up, and clinical endpoints. They do not establish that raising blood NAD+ improves aging in healthy adults.

The sensible verdict is modest: buy NR or NMN only if you value the measured biomarker change itself and accept that 1 g/day—not a standard 300 mg dose—is what the head-to-head trial tested. Do not treat a doubled blood NAD+ value as a receipt for better health.